Proportion of Reported Incremental Cost-Effectiveness Ratios Below Reported Willingness-to-Pay Threshold.

Brendan L. Limone (405941)
William L. Baker (405942)
Jeffrey Kluger (405943)
Craig I. Coleman (287485)

Publication date

April 2013

DOI

10.1371/journal.pone.0062183.g002

Abstract

<p>*Includes results of dabigatran compared to “real-world prescribing”, “trial-like” warfarin control and genotype-guided warfarin †Includes results of dabigatran compared to “trial-like” warfarin control and genotype-guided warfarin.</p

Extracted data

We use cookies to provide a better user experience.

Data Protection

Proportion of Reported Incremental Cost-Effectiveness Ratios Below Reported Willingness-to-Pay Threshold.

Abstract

Extracted data

Proportion of Reported Incremental Cost-Effectiveness Ratios Below Reported Willingness-to-Pay Threshold.

Abstract

Extracted data

Related items

Related items